Nicolas Dugré, Adrienne J Lindblad, Danielle Perry, G Michael Allan, Émélie Braschi, Jamie Falk, Liesbeth Froentjes, Scott R Garrison, Jessica E M Kirkwood, Christina S Korownyk, James P McCormack, Samantha S Moe, Allison Paige, Jen Potter, Betsy S Thomas, Joey Ton, Jennifer Young, Justin Weresch, Michael R Kolber
OBJECTIVE: To assess the benefits and harms of lipid-lowering therapies used to prevent or manage cardiovascular disease including bile acid sequestrants (BAS), ezetimibe, fibrates, niacin, omega-3 supplements, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, and statins. DATA SOURCES: MEDLINE, the Cochrane Database of Systematic Reviews, and a grey literature search. STUDY SELECTION: Systematic reviews of randomized controlled trials published between January 2017 and March 2022 looking at statins, ezetimibe, PCSK9 inhibitors, fibrates, BAS, niacin, and omega-3 supplements for preventing cardiovascular outcomes were selected...
October 2023: Canadian Family Physician Médecin de Famille Canadien